Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2005 5
2006 5
2007 5
2008 4
2009 4
2010 5
2011 3
2012 1
2013 4
2014 6
2015 7
2016 8
2017 17
2018 9
2019 15
2020 18
2021 26
2022 23
2023 22
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
[Chronic eye pain].
Erlenwein J, Petzke F, Tavernini T, Heindl LM, Feltgen N. Erlenwein J, et al. Among authors: feltgen n. Ophthalmologie. 2023 Dec;120(12):1216-1225. doi: 10.1007/s00347-023-01957-8. Epub 2023 Nov 24. Ophthalmologie. 2023. PMID: 37999754 Review. German.
Reply.
Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, Lang GE, Rehak M, Wolf A, Bertelmann T, Hattenbach LO. Hoerauf H, et al. Among authors: feltgen n. Am J Ophthalmol. 2016 Sep;169:292-293. doi: 10.1016/j.ajo.2016.06.016. Epub 2016 Jul 9. Am J Ophthalmol. 2016. PMID: 27401725 No abstract available.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
[Chronic pain in ophthalmology].
Erlenwein J, Feltgen N. Erlenwein J, et al. Among authors: feltgen n. Ophthalmologie. 2023 Dec;120(12):1202-1203. doi: 10.1007/s00347-023-01950-1. Epub 2023 Nov 6. Ophthalmologie. 2023. PMID: 37930370 German. No abstract available.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
[Acute pain therapy following ophthalmic surgery].
Feltgen N, Erlenwein J. Feltgen N, et al. Ophthalmologie. 2023 Jul;120(7):690-691. doi: 10.1007/s00347-023-01889-3. Epub 2023 Jul 7. Ophthalmologie. 2023. PMID: 37417987 German. No abstract available.
[Retinal Vascular Occlusion: Modern Therapeutic Approaches].
Pettenkofer M, Feltgen N, Feucht N, Lohmann CP, Maier MM. Pettenkofer M, et al. Among authors: feltgen n. Klin Monbl Augenheilkd. 2018 Jul;235(7):830-839. doi: 10.1055/s-0043-106302. Epub 2017 Jul 27. Klin Monbl Augenheilkd. 2018. PMID: 28750436 Review. German.
Loss of Visual Acuity Following Acupuncture.
Drüke D, Feltgen N, Hoerauf H. Drüke D, et al. Among authors: feltgen n. Dtsch Arztebl Int. 2022 Sep 30;119(39):663. doi: 10.3238/arztebl.m2022.0222. Dtsch Arztebl Int. 2022. PMID: 36594283 Free PMC article. No abstract available.
161 results